This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cormier, J. N. Articles by Du, X. L. Search for Related Content PubMed PubMed Citation Articles by Cormier, J. N. Articles by Du, X. L. Pubmed/NCBI databases Medline Plus Health Information Melanoma Skin Cancer Social Bookmarking                            What's this?

Population-Based Assessment of Surgical Treatment Trends for Patients With Melanoma in the Era of Sentinel Lymph Node Biopsy

From The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Janice N. Cormier, MD, MPH, Department of Surgical Oncology, Unit 444, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, PO Box 301402, Houston, TX 77230-1402; e-mail: jcormier{at}mdanderson.org

PURPOSE: The surgical staging of melanoma dramatically changed with the introduction of sentinel lymph node (SLN) biopsy. In this study, Surveillance, Epidemiology, and End Results (SEER) data were examined to determine how surgical treatment is being carried out and whether SLN biopsy is being performed in melanoma patients in conformance with National Comprehensive Cancer Network (NCCN) guidelines.

PATIENTS AND METHODS: The SEER database (1998 to 2001) was searched for all patients with invasive melanoma. NCCN guidelines were used to define optimal stage-specific surgical treatment. Treatment trends in patients with stages I to III disease were summarized, and multivariate analyses were performed to identify factors associated with nonadherence with treatment guidelines.

RESULTS: A total of 21,867 melanoma patients were identified; 18,499 of these patients met the inclusion criteria. The number of patients diagnosed with stage III melanoma increased by 55.7% over the study period, and this corresponded to a 53% increase in the number of SLN biopsies performed annually. The odds ratios for nonadherence were 2.32, 2.27, and 1.54 for stages IB, II, and III disease, respectively, compared with stage IA melanoma. Multivariate analyses revealed that age more than 65 years, marital status, minority populations, and primary tumor location were associated with nonadherence with guidelines. Treatment patterns among tumor registries also varied significantly.

CONCLUSION: Stage migration is evident in the SEER registries in consort with increasing use of SLN biopsy. Although treatment trends are improving, SLN biopsy continues to be underused, particularly in the elderly and minority populations, in patients with truncal and head/neck melanomas, and also in some geographic regions of the United States.

Supported by National Cancer Institute Clinical Oncology Research Development Program grant No. 5-K12-CA088084.

Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Y. Bilimoria, C. M. Balch, J. D. Wayne, D. C. Chang, B. E. Palis, S. M. Dy, and J. R. Lange Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States J. Clin. Oncol., April 10, 2009; 27(11): 1857 - 1863. [Abstract] [Full Text] [PDF]

				F. Grange, F. Vitry, F. Granel-Brocard, D. Lipsker, F. Aubin, G. Hedelin, S. Dalac, F. Truchetet, C. Michel, M.-L. Batard, et al. Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France Arch Dermatol, May 1, 2008; 144(5): 629 - 636. [Abstract] [Full Text] [PDF]

				A. M. Lachiewicz, M. Berwick, C. L. Wiggins, and N. E. Thomas Survival Differences Between Patients With Scalp or Neck Melanoma and Those With Melanoma of Other Sites in the Surveillance, Epidemiology, and End Results (SEER) Program Arch Dermatol, April 1, 2008; 144(4): 515 - 521. [Abstract] [Full Text] [PDF]

				J. R. Lange and C. M. Balch Melanoma in Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 399 - 402. [Abstract] [Full Text] [PDF]

				C. A. Reyes Ortiz, J. L. Freeman, Y.-F. Kuo, and J. S. Goodwin The Influence of Marital Status on Stage at Diagnosis and Survival of Older Persons With Melanoma J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 892 - 898. [Abstract] [Full Text] [PDF]

				M. L. Pennie, S. L. Soon, J. B. Risser, E. Veledar, S. D. Culler, and S. C. Chen Melanoma Outcomes for Medicare Patients: Association of Stage and Survival With Detection by a Dermatologist vs a Nondermatologist Arch Dermatol, April 1, 2007; 143(4): 488 - 494. [Abstract] [Full Text] [PDF]

				S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al. Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513. [Abstract] [Full Text] [PDF]

				P. A. Gimotty, D. E. Elder, D. L. Fraker, J. Botbyl, K. Sellers, R. Elenitsas, M. E. Ming, L. Schuchter, F. R. Spitz, B. J. Czerniecki, et al. Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas J. Clin. Oncol., March 20, 2007; 25(9): 1129 - 1134. [Abstract] [Full Text] [PDF]

				J. N. Cormier, Y. Xing, M. Ding, J. E. Lee, P. F. Mansfield, J. E. Gershenwald, M. I. Ross, and X. L. Du Ethnic differences among patients with cutaneous melanoma. Arch Intern Med, September 25, 2006; 166(17): 1907 - 1914. [Abstract] [Full Text] [PDF]